Introduction and Objectives: There is some controversy over the clinical efficacy of Hydroxy urea in Thalassemia intermedia.
Materials and Methods: Therapeutic efficacy of Hydroxy urea was evaluated in 16 patients with thalassemia intermedia, by measuring total hemoglobin and hemoglobin F levels before and 6months after treatment with Hydroxy urea (20mg/kg/day).
Results: Mean increases in total hemoglobin and hemoglobin F levels 6mo after treatment with Hydroxy urea were 1.47±1.12gm/dl and 1.43±1.12 gm/dl, respectively. The most common mutation was found to be IV S II-I betaglobin.
Discussion and Conclusions: Use of Hydroxy urea in thalassemia intermedia is associated with increases in total hemoglobin and hemoglobin F levels.
IV S II-I mutation
The full text of this article is available on PDF
© 2002, Journal of Kermanshah University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.